© CEOCFO Magazine -
CEOCFO Magazine, PO Box 340
Palm Harbor, FL 34682-
Lynn Fosse, Senior Editor
Steve Alexander, Associate Editor
Bud Wayne, Marketing
& Production Manager
Christy Rivers -
Dr. Triantafyllos (Fyl) Tafas
Triantafyllos Tafas PhD
Interview conducted by:
Lynn Fosse, Senior Editor
Published – June 14, 2021
CEOCFO: Dr. Tafas, what was the vision when you founded QCDx, LLC and what is your focus today?
Dr. Tafas: The vision behind founding QCDx was to deliver real time and precise detection of cancer and to enable precision medicine. Accordingly, the RareScope 3-
CEOCFO: What is your approach? How does it differ from what other methods are available today?
Dr. Tafas: We developed the RareScope™ technology to address the unmet need of characterizing cellular heterogeneity which is the hallmark of cancer. Cancer cells are genetically abnormal, and as they divide, they create offspring cells that are also abnormal and potentially different from their parent. This simply means that a cellular marker that could be a therapeutic target in a paternal cancer cell, may not exist in its offspring cells which may end up creating treatment-
Sampling cancer cells and mapping heterogeneity through repeated tissue biopsies is rarely possible because of the tissue biopsy invasiveness. However, tumors are releasing cancer cells in the blood starting early at the disease onset. These are known as Circulating Tumor Cells (CTCs) and can be detected via a simple blood draw that can be repeated often. CTCs are live representatives of the tumor’s heterogeneity and can be very rare among blood cells, down to one per milliliter of blood. With sensitive detection, CTCs can provide real-
The RareScope is designed for sensitive and unbiased CTC detection. It does that by analyzing nucleated cells from the patient’s blood sample in an immobilized suspension, after staining with fluorescent probes that target cancer-
CEOCFO: What is it about your equipment that allows you to find this?
Dr. Tafas: The RareScope is using fluorescence, 3-
CEOCFO: Is the medical community onboard? Do the people who should know about QCDx know about you? Do they understand the difference or is there still a lot of education yet to be done?
Dr. Tafas: The company has been operating for the past three years and we are developing close contacts with leading medical oncology groups from major Cancer Centers. We are excited that Senior Clinical Oncologists appreciate the benefits that RareScope-
In a second clinical study with the Duke University, Brain Cancer Center we shall work for disease characterization and treatment optimization in glioblastoma. Patient enrollment is projected to begin in October 2021, and the Neuro-
Working with our Oncology Advisors we are extending outreach to other Clinical Oncology Groups around the country, to show how clinical results obtained by RareScope support personalized and real-
CEOCFO: Are there certain cancers that are more appropriate for this approach? What have you found so far?
Dr. Tafas: We believe that our technology can contribute significantly in precision medicine of different disease types. Our initial focus was set to breast cancer because it is the most common among American women and we aim to be a major lever for clinical oncologists to fighting back early stage and advancing or metastatic breast cancer. Glioblastoma is a more rare but fast-
Drawing experience from these two studies in very different disease types, we believe that after appropriate selection of molecular targets, our technology will be applicable to lung and other types of tissue cancer as well as to blood cancers.
CEOCFO: Would you tell us about the different products you have available and how they are used?
Dr. Tafas: The main component in our product offering is the RareScope, for cancer research, biopharmaceutical product development, and for clinical cancer diagnosis. The first instrument is scheduled to be delivered to the University of Connecticut Cancer Center in July 2021 where it will be used for cancer research.
We are introducing the RareScope to other Cancer Research Centers for basic and applied cancer research as well as to biopharmaceutical companies where it can contribute in all clinical trial phases of cancer therapeutic development. A major goal for us is to offer the RareScope as a medical device to benefit patients from the diagnostic phase through their treatment trajectories and past-
QCDx is also developing the MultiFluor™ technology and products for multiplex, immunofluorescent staining of intact and live cell preparations visualized with the RareScope as well as for cell preparations made on glass slides. This will enable characterization of detected cancer cells with more than two dozen biomarkers and expand on the number of detected treatment targets. Since the RareScope visualizes all nucleated cells from the patient’s blood sample, MultiFluor probes can offer simultaneous characterization of lymphocytes and enhance real-
CEOCFO: What surprised you from the founding of the company, from the original idea, to where you are today?
Dr. Tafas: Presence of circulating tumor cells in the blood has been known for more than 100 years, but despite the existence of CTC detection systems since the beginning of the 2000s, CTCs have not become the important tool they can be for cancer diagnosis when a biopsy is not possible. We believe that the QCDx enrichment-
CEOCFO: Are you seeking funding, investment or partnerships?
Dr. Tafas: We are. The company is working on an institutional financing round and our goal is to raise four to six million dollars over the coming few months. At the same time, we are looking into partnering with pharmaceutical companies, for collaborations in the development of cancer therapeutics.
CEOCFO: There are so many ideas in the medical field that should be looked at. Why does QCDx standout? Why pay attention?
Dr. Tafas: Cancer changes continually as it grows and the QCDx technology can characterize the changes in real time at the cellular level to fight back the disease. When tissue biopsy is not an option, circulating tumor cells are the best source of information for optimizing treatment and counter the disease growth. At the same time, immune cell characterization can help in optimizing immunotherapeutic treatments. The QCDx technology can offer both, starting from a minimally invasive blood sample. We believe this will fulfill our mission to create a solution for precise oncology that benefits the patients’ treatment outcomes and improves their quality of life.
QCDx LLC | Dr. Triantafyllos (Fyl) Tafas | Detect Circulating Tumor CELLS | Rare Cell Detection The innovative QCDx technology may lead to truly optimized cancer treatment and have a significant impact on patient outcomes. | CEO Interviews 2021 | Medical Companies | Quantitative Cell Diagnostix, Quantitative Cell Diagnostics, Reveal CTC heterogeneity, reveal circulating tumor cell heterogeneity, A Rare Cell Detection for Cancer, rare cancer cell detection, instruments, consumables and reagents for the detection of rare cells in the blood circulation, reveal circulating tumor cell heterogeneity early in cancer onset, intact cell visualization, live cell visualization, single cell isolation, 3D-
“The RareScope™ maintains focus on characterizing cancer heterogeneity by enrichment-
Dr. Triantafyllos (Fyl) Tafas